277327-89-6

Basic information

• Product Name: tert-butyl 3-(((6-((tert-butoxy)carbonylamino)hexyl)amino)methyl)-4-fluorobenzoate
• CAS NO: 277327-89-6
• Molecular Weight: 424.556
• Mol File: 277327-89-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-(((6-((tert-butoxy)carbonylamino)hexyl)amino)methyl)-4-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(((6-((tert-butoxy)carbonylamino)hexyl)amino)methyl)-4-fluorobenzoate(277327-89-6)
• EPA Substance Registry System: tert-butyl 3-(((6-((tert-butoxy)carbonylamino)hexyl)amino)methyl)-4-fluorobenzoate(277327-89-6)

Safety Data

• Hazardous Substances Data: 277327-89-6(Hazardous Substances Data)

Upstream product

• 65915-94-8 N-(tert-butoxycarbonyl)-1,6-diaminohexane hydrochloride 
• 193473-82-4 tert-butyl-4-fluoro-3(alpha-bromomethyl)benzoate 

Relevant articles and documents

Vitronectin receptor antagonist pharmaceuticals

The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.